Chronic Pain > Ketamine

Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting

(Ketamine Trial)

Recruiting in Palo Alto (17 mi)

Overseen By Lucinda Grande, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: University of Washington

Pivotal Trial (Near Approval)

Prior Safety Data

Approved in 5 jurisdictions

Trial Summary

What is the purpose of this trial?

This project is a pilot study to evaluate the analgesic and opioid-sparing effects of ketamine in an ultra-low dose oral formulation as a novel intervention for treatment of chronic non-cancer pain in opioid-tolerant patients in the primary care outpatient setting.

Eligibility Criteria

Participant Groups

Group I: Active Drug Active Control 1 Intervention

ketamine 16 mg in flavored syrup by mouth twice daily for 1 week, then ketaming 32 mg in flavored syrup by mouth twice daily for 1 week

Group II: Placebo Placebo Group 1 Intervention

Flavored syrup (without ketamine) by mouth twice daily for 2 weeks

Ketamine is already approved in United States, European Union, United States, European Union, Canada for the following indications:

🇺🇸 Approved in United States as Ketalar for:

• Anesthesia
• Treatment-resistant depression

🇪🇺 Approved in European Union as Ketalar for:

• Anesthesia
• Treatment-resistant depression

🇺🇸 Approved in United States as Spravato for:

• Treatment-resistant depression

🇪🇺 Approved in European Union as Spravato for:

• Treatment-resistant depression

🇨🇦 Approved in Canada as Spravato for:

• Treatment-resistant depression

Find A Clinic Near You

Research locations nearby Select from list below to view details:

Pioneer Family Practice Lacey, WA

Who is running the clinical trial?

University of Washington Lead Sponsor

References